JP2019515033A5 - - Google Patents

Download PDF

Info

Publication number
JP2019515033A5
JP2019515033A5 JP2019507069A JP2019507069A JP2019515033A5 JP 2019515033 A5 JP2019515033 A5 JP 2019515033A5 JP 2019507069 A JP2019507069 A JP 2019507069A JP 2019507069 A JP2019507069 A JP 2019507069A JP 2019515033 A5 JP2019515033 A5 JP 2019515033A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
day
composition according
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019507069A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515033A (ja
JP6931042B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/029120 external-priority patent/WO2017185087A1/en
Publication of JP2019515033A publication Critical patent/JP2019515033A/ja
Publication of JP2019515033A5 publication Critical patent/JP2019515033A5/ja
Application granted granted Critical
Publication of JP6931042B2 publication Critical patent/JP6931042B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019507069A 2016-04-22 2017-04-24 甲状腺ベータアゴニストの使用 Active JP6931042B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662326436P 2016-04-22 2016-04-22
US62/326,436 2016-04-22
PCT/US2017/029120 WO2017185087A1 (en) 2016-04-22 2017-04-24 Use of thyroid beta-agonists

Publications (3)

Publication Number Publication Date
JP2019515033A JP2019515033A (ja) 2019-06-06
JP2019515033A5 true JP2019515033A5 (https=) 2020-06-11
JP6931042B2 JP6931042B2 (ja) 2021-09-01

Family

ID=60116400

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019507069A Active JP6931042B2 (ja) 2016-04-22 2017-04-24 甲状腺ベータアゴニストの使用

Country Status (10)

Country Link
US (3) US11351183B2 (https=)
EP (1) EP3445373B1 (https=)
JP (1) JP6931042B2 (https=)
KR (1) KR102407059B1 (https=)
AU (1) AU2017252126B2 (https=)
BR (1) BR112018071586A2 (https=)
CA (1) CA3021681C (https=)
ES (1) ES2992773T3 (https=)
MX (1) MX385085B (https=)
WO (1) WO2017185087A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017252126B2 (en) 2016-04-22 2023-02-09 Metabasis Therapeutics, Inc. Use of thyroid beta-agonists
ES3053674T3 (en) * 2018-03-22 2026-01-23 Viking Therapeutics Inc Crystalline forms and methods of producing crystalline forms of a compound
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
US11752161B2 (en) 2020-03-27 2023-09-12 Gannex Pharma Co., Ltd. Pharmaceutical compositions, method of making and method of using thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
CA2543132A1 (en) 2003-10-23 2005-05-19 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
CA2584845C (en) 2004-12-08 2009-02-17 Sirion Therapeutics, Inc. Methods, assays and compositions for treating retinol-related diseases
WO2006128056A2 (en) * 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Novel phosphinic acid-containing thyromimetics
MX2007014502A (es) 2005-05-26 2008-02-07 Metabasis Therapeutics Inc Tiromimeticos para el tratamiento de enfermedades del higado graso.
US20090042857A1 (en) 2006-02-20 2009-02-12 Masuo Yamaoka Novel Pharmaceutical
US20110071208A1 (en) 2009-06-05 2011-03-24 Protiva Biotherapeutics, Inc. Lipid encapsulated dicer-substrate interfering rna
WO2011038207A1 (en) * 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
MX390699B (es) 2011-06-21 2025-03-21 Alnylam Pharmaceuticals Inc Composiciones y metodos para inhibicion de genes para apolipoproteina c-iii (apoc3).
WO2014178892A1 (en) * 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
PE20180021A1 (es) 2015-02-20 2018-01-09 Univ Oregon Health & Science Derivados de sobetiroma
RU2719245C2 (ru) 2016-02-29 2020-04-17 Филип Моррис Продактс С.А. Тара и заготовка с шарнирной крышкой
AU2017252126B2 (en) 2016-04-22 2023-02-09 Metabasis Therapeutics, Inc. Use of thyroid beta-agonists
BR112018071559B1 (pt) 2016-04-22 2024-02-06 Viking Therapeutics, Inc Uso de um agonista de receptor beta de hormônios da tireoide para o tratamento de adrenoleucodistrofia ligada ao x
DK3457851T3 (da) 2016-05-18 2021-09-20 Univ Oregon Health & Science Derivater af sobetirom

Similar Documents

Publication Publication Date Title
JP2020097577A5 (https=)
JP2017518334A5 (https=)
JP2018534348A5 (https=)
JP2018111728A5 (https=)
RU2018114447A (ru) Введение дейтерированных усилителей cftr
JP2017513836A5 (https=)
CN109415406A (zh) 羊毛甾醇前药化合物及其制备方法和应用
JP2016515561A5 (https=)
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
JP2018531941A5 (https=)
JP2019515033A5 (https=)
JP2015155440A5 (https=)
JP2017505285A5 (https=)
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
JP2018530578A5 (https=)
JP2014218522A5 (https=)
JP2016534081A5 (ja) ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法
JP2017508817A5 (https=)
JP2017502074A5 (https=)
JP2018521056A5 (https=)
JP2018530608A5 (https=)
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
JP2018524306A5 (https=)
EA201791138A1 (ru) Фармацевтическая композиция, ее приготовление и применения
RU2018146504A (ru) Лечение внутрипеченочных холестатических заболеваний